
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 5% in the afternoon session after the company's study of BL1332 did not show a statistically significant improvement on its primary 24-hour pain-relief endpoint.
According to a company press release, the study did not meet its primary endpoint of demonstrating a statistically significant improvement versus vehicle in the sum of pain intensity differences (SPID) over 24 hours. The release showed a least-squares mean difference versus vehicle of -11.5 for BL1332 0.30% and -9.0 for BL1332 0.15%, with negative values favoring BL1332 indicating greater pain relief.
Shares may have fallen because failing to reach statistical significance on that measure weakened the evidence of efficacy for BL1332 and left its next development steps uncertain.
After the initial drop, the shares shed some of the losses and rose to $19.75, down 4.5% from the previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Bausch + Lomb? Access our full analysis report here, it’s free.
Bausch + Lomb’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 23 days ago when the stock gained 8.7% on the news that the company reported third-quarter 2026 revenue of $1.375 billion and raised its full-year 2026 revenue guidance. According to a company press release, Bausch + Lomb reported total revenue of $1.375 billion, up 7% compared to the prior-year period, with constant currency revenue rising 8% across its vision care, pharmaceutical, and surgical divisions. Adjusted earnings per share was 34 cents, up from 18 cents in the same quarter last year and above analysts' consensus estimates of 22 cents. Adjusted EBITDA was $325 million, above analyst estimates of $270.9 million.
For the full year, the company lifted its revenue guidance to $5.5 billion at the midpoint from $5.49 billion. Full-year EBITDA guidance of $1.12 billion at the midpoint was also above analyst estimates of $1.05 billion.
Bausch + Lomb is up 19.1% since the beginning of the year, and at $19.75 per share, it is trading close to its 52-week high of $21.37 from November 2026. Investors who bought $1,000 worth of Bausch + Lomb’s shares at the IPO in May 2022 would now be looking at an investment worth $987.50.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.